← Back to Analyst Consensus 
OTLK Buy
Outlook Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 11, 2026 | Ascendiant Capital | maintain | Buy → Buy | — | 38% |
| Aug 14, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jul 27, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | — | 44% |
| Jul 27, 2026 | BTIG | upgrade | Neutral → Buy | — | 52% |
| Jun 11, 2026 | Ascendiant Capital | maintain | Buy → Buy | — | 38% |
| May 18, 2026 | BTIG | downgrade | Buy → Neutral | — | 52% |
| Mar 11, 2026 | Ascendiant Capital | maintain | Buy → Buy | $6 | 38% |
| Feb 18, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0.5 | 44% |
| Feb 18, 2026 | Chardan Capital | maintain | Neutral → Neutral | $1 | 47% |
| Jan 5, 2026 | Chardan Capital | maintain | Neutral → Neutral | $1 | 47% |
| Jan 2, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | $0.5 | 44% |
| Dec 22, 2025 | Ascendiant Capital | maintain | Buy → Buy | $10 | 38% |
| Sep 30, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $1 | 44% |
| Sep 22, 2025 | Ascendiant Capital | maintain | Buy → Buy | $8 | 38% |
| Aug 29, 2025 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Aug 29, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $1 | 44% |
| Aug 28, 2025 | Chardan Capital | maintain | Neutral → Neutral | $3 | 47% |
| Aug 15, 2025 | Chardan Capital | maintain | Neutral → Neutral | $3 | 47% |
| Jun 6, 2025 | Ascendiant Capital | maintain | Buy → Buy | $21 | 38% |
| Feb 24, 2025 | Ascendiant Capital | maintain | Buy → Buy | $24 | 38% |
| Feb 18, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $3 | 44% |
| Feb 18, 2025 | Chardan Capital | maintain | Neutral → Neutral | $3 | 47% |
| Jan 17, 2025 | Guggenheim | reiterate | Buy → Buy | $12 | 52% |
| Jan 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Dec 2, 2024 | Chardan Capital | downgrade | Buy → Neutral | $0 | 47% |
| Nov 29, 2024 | BTIG | maintain | Buy → Buy | $9 | 52% |
| Nov 29, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Aug 16, 2024 | Chardan Capital | maintain | Buy → Buy | $53 | 47% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| May 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Mar 27, 2024 | BTIG | upgrade | Neutral → Buy | $50 | 52% |
| Mar 25, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $30 | 44% |
| Feb 15, 2024 | Chardan Capital | upgrade | Neutral → Buy | $3 | 47% |
| Jan 25, 2024 | Guggenheim | upgrade | Neutral → Buy | $2 | 52% |
| Jan 25, 2024 | Brookline Capital | upgrade | Hold → Buy | $1.57 | 38% |
| Dec 29, 2023 | Ascendiant Capital | maintain | Buy → Buy | $2 | 38% |
| Dec 27, 2023 | Capital One | upgrade | Equal-Weight → Overweight | $5 | 30% |
| Nov 3, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $2 | 44% |
| Aug 31, 2023 | Chardan Capital | downgrade | Buy → Neutral | $0 | 47% |
| Aug 31, 2023 | HC Wainwright & Co. | downgrade | Buy → Neutral | $1 | 44% |
| Aug 30, 2023 | Brookline Capital | downgrade | Buy → Hold | $0 | 38% |
| Aug 30, 2023 | Cantor Fitzgerald | downgrade | Overweight → Neutral | $1 | 50% |
| Aug 30, 2023 | BTIG | downgrade | Buy → Neutral | $0 | 52% |
| Aug 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Aug 15, 2023 | Chardan Capital | reiterate | Buy → Buy | $10 | 47% |
| Jul 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Jul 13, 2023 | Capital One | initiate | — → Overweight | $5 | 30% |
| May 16, 2023 | Chardan Capital | reiterate | Buy → Buy | $10 | 47% |
| May 16, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Apr 3, 2023 | Guggenheim | initiate | — → Buy | $5 | 52% |
Price Target Trend
Jun 10, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days